Skip to main
INVA

Innoviva (INVA) Stock Forecast & Price Target

Innoviva (INVA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 20%

Bulls say

Innoviva Inc. has demonstrated robust revenue growth through its portfolio of royalty and healthcare assets, with annual sales for Giapreza increasing by 33% from 2023 to 2024 and maintaining significant growth for Xerava above 20% since acquisition. The company's strategic acquisitions have outperformed their previous owners, with Giapreza and Xerava's annualized run rates nearly doubling since Innoviva acquired them in August 2022. Additionally, Giapreza's net sales rose from $33.4 million in 2021 to $41.3 million in 2023, reflecting a 24% increase, and are projected to reach $55 million in 2024, highlighting the company's effective asset management and sales strategies.

Bears say

Innoviva Inc. faces a negative outlook primarily due to projected declines in royalties from its key products, with expectations of an average year-over-year decrease of -8% for Relvar/Breo and -4% for Anoro over the next eight years. Additionally, the anticipated loss of exclusivity for Giapreza in 2034 further compounds risks to future revenue streams, as it is expected to significantly impact revenue generation in critical care and infectious disease markets. The company may encounter increased competitive pressures over time, although the difficulty of genericizing its drugs due to challenges in engineering competing delivery devices offers some mitigation against severe declines, yet overall, the financial trends suggest weakening performance prospects.

Innoviva (INVA) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 20% predict a Strong Sell.

This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Innoviva (INVA) Forecast

Analysts have given Innoviva (INVA) a Buy based on their latest research and market trends.

According to 5 analysts, Innoviva (INVA) has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Innoviva (INVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.